VAXIMM
company
About
VAXIMM is a vaccine company offers VXM01 targeting tumor vasculature.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- Fr7.80M
- Industries
- Biotechnology,Developer Platform,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
Fr7.80M
VAXIMM has raised a total of
Fr7.80M
in funding over 2 rounds. Their latest funding was raised on
Jan 12, 2011 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 12, 2011 | Series Unknown | Fr7.80M | 1 |
Merck
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
VAXIMM is funded by 1 investors.
Merck
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Merck
|
Yes | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
